atrial fibrillation gene therapy (Northwest University/Rhythm Therapeutics)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nameatrial fibrillation gene therapy (Northwest University/Rhythm Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Plasmid
Mechanisms of ActionTransforming growth factor beta receptor 2 stimulants
TargetsTransforming growth factor beta receptor 2
Therapy Area/IndicationsAtrial Fibrillation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNorthwestern University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInomagen Therapeutics IncNorthwestern University
Active IndicationsN/A
Inactive IndicationsAtrial Fibrillation

Other Information

ATC CodeN/A
Related LinksN/A